Versameb Strengthens its Board of Directors
- Significant appointments of experienced drug development and financial experts – Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut
Versameb AG (“Versameb”), transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut to its board of directors as it prepares to enter clinical development with lead candidate, VMB-100, an RNA-based therapy for the treatment of Stress Urinary Incontinence (SUI).
